JOURNAL SCANS: RESEARCH

Page 1 of 281

« start ‹ previous ... 1 2 3 4 5 ... next › end »

The Degree of Neutropenia Has a Prognostic Impact in Low Risk Myelodysplastic Syndrome

I Cordoba, JR Gonzalez-Porras, E Such, MC Canizo, et al, 2012 Mar 1, Leuk Res

In this examination of the prognostic significance of severe neutropenia in patients with de novo myelodysplastic syndrome and low to intermediate-1 IPSS, multivariate analysis revealed that severe neutropenia...

High Non-Compliance in the Use of Letrozole After 2.5 Years of Extended Adjuvant Endocrine Therapy. Results From the IDEAL Randomized Trial

DBY Fontein, JWR Nortier, GJ Liefers, CJH van de Velde Liefers, et al, 2012 Feb 1, Eur J Surg Oncol

Data from this prospective phase III trial highlight the issue of early discontinuation of aromatase inhibitors as extended adjuvant therapy in women with ER-positive breast cancer. The optimal approach...

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

G von Minckwitz, H Eidtmann, M Rezai, P Fasching, H Tesch, H Eggemann, I Schrader, K Kittel, C Hanusch, R Kreienberg, C Solbach, B Gerber, C Jackisch, G Kunz, J Blohmer, J Huober, M Hauschild, T Fehm, B Maria Muller, C Denkert, S Loibl, V Nekljudova, M Untch, 2012 Jan 26, N Engl J Med

EXPERT COMMENTARY

In this randomized phase III study, the addition of bevacizumab to neoadjuvant chemotherapy increased the rate of pathologic complete response in patients with operable or locally advanced HER2-negative...

Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer

H Bear, G Tang, P Rastogi, C Geyer, Jr., A Robidoux, J Atkins, L Baez-Diaz, A Brufsky, R Mehta, L Fehrenbacher, J Young, F Senecal, R Gaur, R Margolese, P Adams, H Gross, J Costantino, S Swain, E Mamounas, N Wolmark, 2012 Jan 26, N Engl J Med

In this randomized study in women with operable HER2-negative breast cancer, addition of capecitabine or gemcitabine to neoadjuvant taxane-based therapy did not improve response, whereas addition of bevacizumab...

Erlotinib Versus Standard Chemotherapy as First-Line Treatment for European Patients With Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (EURTAC): A Multicentre, Open-Label, Randomised Phase 3 Trial

R Rosell, E Carcereny, R Gervais, A Illiano, et al, 2012 Jan 25, Lancet Oncol

Results of this first randomized controlled trial of erlotinib vs chemotherapy in patients with EGFR-positive NSCLC showed that erlotinib improved PFS with fewer serious adverse effects. Abstract Background:...

Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial

B von Tresckow, A Plutschow, M Fuchs, B Klimm, J Markova, A Lohri, Z Kral, R Greil, MS Topp, J Meissner, JM Zijlstra, M Soekler, H Stein, HT Eich, RP Mueller, V Diehl, P Borchmann, A Engert, 2012 Jan 23, J Clin Oncol

SUMMARY OncologySTAT Editorial Team Standard chemotherapy for early unfavorable Hodgkin’s lymphoma (HL)— four cycles of ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine) and 30 Gy involved-field...

Trastuzumab for Treatment of Refractory/Relapsed HER2-Positive Adult B-ALL: Results of a Phase II GRAALL Study

P Chevallier, N Robillard, A Charbonnier, H Dombret, et al, 2012 Jan 20, Blood

This small phase II study demonstrated that monotherapy with trastuzumab elicited responses in refractory/relapsed very–high risk adult patients with HER2-positive B-cell acute lymphocytic leukemia. Abstract The...

Neoadjuvant Anastrozole Versus Tamoxifen in Patients Receiving Goserelin for Premenopausal Breast Cancer (STAGE): A Double-Blind, Randomised Phase 3 Trial

N Masuda, Y Sagara, T Kinoshita, S Noguchi, et al, 2012 Jan 20, Lancet Oncol

Results of this phase III study of premenopausal women with ER-positive, HER2-negative breast cancer showed a better response rate with neoadjuvant anastrozole plus goserelin vs with tamoxifen plus goserelin. Abstract Background:...

RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

F Su, A Viros, C Milagre, K Trunzer, R Marais, et al, 2012 Jan 19, N Engl J Med

This was a molecular analysis designed to identify oncogenic mutations in cutaneous squamous cell carcinomas and keratoacanthomas that develop early in a subset of patients with vemurafenib–treated melanoma....

A Phase II Study of Gefitinib for Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck

CM Lewis, BS Glisson, L Feng, RS Weber, et al, 2012 Jan 18, Clin Cancer Res

In a small phase II study, gefitinib showed promise as neoadjuvant therapy in patients with aggressive cutaneous squamous cell carcinomas, with an overall disease control rate of 45.5%. SUMMARY OncologySTAT...

« start ‹ previous ... 1 2 3 4 5 ... next › end »

Page 1 of 281

Comment Print page RSS feeds

About Our Journal Scans

View a list of journals that the OncologySTAT editorial team scans every week in order to bring you the most practice-relevant original research and review articles.

View list ›

Sign up for our newsletters

Too busy to follow cancer's top stories? Sign-up for 1 or more of our free newsletters -- delivered weekly to your inbox.

Sign-up now ›